A Leader Who Understands the Journey: Welcoming David Walsey as Bay Area Lyme Foundation’s New Executive Director

Bay Area Lyme Spotlight Series

 

“Science drives our mission, but patient stories remind us why the science matters.”

– David Walsey

As David Walsey steps into his new role as Executive Director of Bay Area Lyme Foundation, he brings more than professional expertise. He brings lived experience of diagnostic uncertainty, immune dysfunction, co-infections, and the long arc many families travel before answers emerge. For patients, caregivers, and supporters of Bay Area Lyme, David’s leadership signals both continuity and momentum: a future rooted in rigorous science, compassionate leadership, and hope grounded in progress. “It’s been a long journey to get here,” David says. “We’ve spent nearly a decade navigating tick-borne disease as a family. That experience changed everything for us.” Dana Parish interviewed David as part of our Ticktective video podcast series. Watch or listen to the complete interview.

When Symptoms Don’t Fit the Textbook

Nearly ten years ago, David’s son began experiencing a constellation of symptoms that defied easy explanation. Despite multiple medical evaluations, no unifying diagnosis emerged. When Lyme disease was finally identified, the family initially felt relief. “I thought this was a solvable, short-term problem,” David recalls. “You treat it, and life goes back to normal.”

Improving Lyme Diagnostics, Biomarkers, and Treatment: Inside Dr. Peter Gwynne’s Research

Peter Gwynne, PhD

Bay Area Lyme Leading the Way series

 

“I wanted to be doing work that was driven by clinical need… and there are a lot of clinical needs in Lyme disease.”

– Peter Gwynne, PhD

Peter Gwynne, PhDFor too many people with Lyme disease, the journey begins with uncertainty. A missed rash. A negative test. Symptoms that don’t make sense. A diagnosis that comes too late, or not at all. Bay Area Lyme Foundation believes this must change. And we believe change happens through funding rigorous science, innovative thinking, and supporting researchers willing to tackle the hardest questions head-on.

One of those scientists is Tufts researcher Peter Gwynne, PhD, a microbiologist whose work sits at the cutting edge of Lyme research and is the recipient of our 2022 Emerging Leader Award. We spoke with Dr. Gwynne to get an inside look at his work and understand how this may impact Lyme patients in the future. His focus is simple to state but complex to achieve: develop better diagnostics, identify meaningful biomarkers, and move the field toward treatments and even prevention strategies that could fundamentally reshape how Lyme disease is understood and managed.

Drawn to Lyme by the Urgency of the Need

Dr. Gwynne did not begin his career in Lyme disease. He trained in molecular microbiology, studying pathogens such as Salmonella and Staphylococcus, the bacteria responsible for serious infections, including those often acquired in hospital settings. But over time, he found himself seeking work that could make a tangible difference for patients.

A Foot-Tapper and Smile-Creator! Lyme Patient Releases New Jazz Album

Steve Erlich

Bay Area Lyme Spotlight Series

 

“Every listen helps fund Lyme research.”

– Steve Ehrlich

 

Steve Ehrlich emigrated to the San Francisco Bay Area from South Africa in 1989. Chronic Lyme Disease cut short his career in the software industry, and he turned to writing music. He has released two contemporary jazz albums with his virtual band, The Inter Section. He spends his days on his sofa writing music with his doggie, Frankie, hitting play and paws when needed. The second jazz album is now available on all the streaming apps, and, like his first album, all the proceeds will be donated to Bay Area Lyme.

We Need a New Generation of Lyme Doctors: James Bruzzese, MD, is Leading the Way

James Bruzzese

Bay Area Lyme Spotlights Series

 

“Some institutions are evolving in research and education, but it’s not translating to clinical practice.”

– James Bruzzese, MD

When James Bruzzese, MD, talks about Lyme disease, he doesn’t speak in abstractions. He speaks as a brother who watched his sister lose her ability to walk; a son who watched his father leave his job to become a full-time caregiver; and as a medical student who sat in lecture halls knowing that what was being taught about Lyme and tick-borne disease was grossly incomplete.

Now, as a young physician preparing to open a practice dedicated to treating Lyme and tick-borne disease patients in New York, James represents something the Lyme community urgently needs: a new generation of doctors who understand that Lyme is real, that patients deserve better, and that the status quo must be challenged.

“It Was Traumatic. We Thought We Might Lose Her.”

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

FOR IMMEDIATE RELEASE

 

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

Milestones include FDA-cleared diagnostics enabled by Lyme Disease Biobank, the launch of Bay Area Lyme Ventures, and 10 years since Lyme Disease Biobank provided its first samples, advancing the field

PORTOLA VALLEY, Calif., February 11, 2026Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research, today reflected on concrete progress in 2025 that demonstrates the maturation of more than a decade of investment in diagnostics, therapeutics, and research infrastructure for Lyme and other tick-borne diseases. As Bay Area Lyme Foundation-supported programs advance towards being available for clinicians and patients, the organization announced David A. Walsey, JD, LLM, as Executive Director. He has extensive experience offering strategic guidance to life sciences companies and a personal connection to Lyme disease that will help guide the foundation’s next phase of scientific translation and organizational growth.

In 2025, Bay Area Lyme Foundation reached an important inflection point as new diagnostic tests enabled by the foundation’s Lyme Disease Biobank secured FDA clearance. These new tests highlight the potential to move from discovery-stage research toward tools that can meaningfully improve patient care. The organization also launched Bay Area Lyme Ventures, an investment arm designed to help promising diagnostics and therapeutics move more efficiently from the laboratory into real-world use, while also creating the opportunity for returns to support future Bay Area Lyme Foundation research. This progress underscores the importance of the more than $30 million in research Bay Area Lyme Foundation has invested at leading academic and medical institutions such as Stanford, Johns Hopkins, Tulane, and Duke. Research supported by the foundation has produced over 70 peer-reviewed scientific publications and sustained collaboration across top research centers nationwide.

Meet David Walsey: Our New Executive Director

Ticktective Podcasts

David A. Walsey, JD, LLM

David Walsey joined Bay Area Lyme Foundation as Executive Director in 2025. He is a strategic biotech leader with 25 years of experience advancing corporate objectives through strategy, communications, financing, and investor initiatives for public companies. Most recently, David served as Senior Vice President, Corporate Affairs at MEI Pharma, leading programs spanning corporate strategy, investor relations, and corporate communications. He previously held senior roles at Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics (formerly AVI BioPharma), Arena Pharmaceuticals, and Maxim Pharmaceuticals, and worked at agencies including Real Chemistry (formerly W20 Group), The Ruth Group, and Noonan Russo. He began his career as an attorney in private practice in New York City and holds an LL.M. in Taxation from New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.

Amy Offutt, MD: Lyme, Integrative Medicine, & True Healing

Amy Offutt, MD

Amy Offutt, MD

Dr. Offutt is the medical director and co-owner of Heart & Soul Integrative Health and Yoga which she co-founded with her husband, Brad, in 2007, located in Marble Falls, Texas. Her first seven years of practice were focused on rural family medicine and obstetrics after which she transitioned to approach the treatment of chronic inflammatory diseases using integrative medicine. She completed medical school at The University of Texas Health Sciences Center in San Antonio and completed a residency in Family Medicine at Christus Health. She has completed a fellowship with the American Academy of Anti-Aging and Regenerative Medicine and has a Master’s Degree in Integrative Medicine from George Washington University.

Bacterial Mechanism That Could Help Prevent and Treat Lyme Arthritis Identified by New Bay Area Lyme Foundation–Supported Study

Brandon Jutras, PhD

FOR IMMEDIATE RELEASE

 

Bacterial Mechanism That Could Help Prevent and Treat Lyme Arthritis Identified by New Bay Area Lyme Foundation–Supported Study

Research published in PLOS Pathogens highlights a cell wall–driven trigger of joint inflammation, pointing to new ways to target Lyme arthritis

PORTOLA VALLEY, Calif., January 20, 2026 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the United States, announced the publication of new research in PLOS Pathogens identifying a novel mechanism that may trigger Lyme arthritis, one of the most common and debilitating complications of Lyme disease in the US. The study provides new insight into how the structure of Borrelia burgdorferi peptidoglycan, a component of the bacterium’s cell wall, and its interaction with a Borrelia protein can provoke joint inflammation. In a preclinical model, subtle changes researchers made to the bacterium’s peptidoglycan structure nearly eliminated arthritis despite ongoing infection, suggesting new approaches to reduce Lyme arthritis and joint damage that may complement antibiotics by targeting inflammatory bacterial components.

“Understanding how these bacterial structures provoke inflammation is an avenue towards new approaches for limiting long-term joint damage and possibly treating patients whose symptoms persist despite standard antibiotic therapy,” said Brandon L. Jutras, PhD, lead author of the study and associate professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine, and a Bay Area Lyme Foundation 2021 Emerging Leader Award winner. “Our findings offer critical insight into how Lyme arthritis is largely driven by specific structural components of Borrelia burgdorferi that may be targeted independent of the other aspects of the infection.”

This new study demonstrates that the chemical makeup and physical structure of peptidoglycan, a structural component of the Borrelia cell wall, play a decisive role in determining whether joint inflammation develops. It also demonstrates how impeding peptidoglycan’s interaction with a specific Borrelia protein may impact the bacterium’s ability to migrate to and persist within joint tissue, resulting in near elimination of Lyme arthritis in the study.

Dr. Casey Kelley: From Lyme & Mold to Optimum Health

Dr Casey Kelley

Bay Area Lyme Spotlight Series

 

Click here to watch or listen now

In a powerful Ticktective™ episode, host Dana Parish sits down with Casey Kelley, MD, Founder and Medical Director of Case Integrative Health, to unpack the complex world of Lyme disease, mold toxicity, environmental illness, and whole-body healing. Dr. Kelley had her own health journey with chronic fatigue, POTS, and other symptoms that led her to specialize in Lyme, tick-borne diseases, mold illness, long COVID, and other complex chronic illnesses. She brings clarity, compassion, and years of integrative and functional medicine experience to help patients understand what’s driving persistent symptoms and what true recovery can look like.

“The nervous system is utterly important to healing. And that entire system gets really thrown off with chronic infections exactly the same way that trauma with a capital T will cause dysfunction in the system.”

– Casey Kelley, MD

A New Year Call to Action After December 15, 2025, HHS Roundtable

Charlotte Mao, MD, MPH

Bay Area Lyme Spotlight Series

By Charlotte Mao, MD, MPH, Bay Area Lyme Foundation

Chronic Lyme Disease patients have been ignored for too long. That must end now.

– Charlotte Mao, MD, MPH

A Long-Overdue Moment of Recognition

Starting in 2026, Lyme disease and other tick-borne disease patients and their families have some reason to be encouraged by the growing recognition of the realities they face and the prospect of continued research to support new diagnostics and treatments.

HHS Lyme Disease Roundtable

 

The December 15, 2025, Department of Health and Human Services (HHS) roundtable marked something rare and long overdue: federal recognition of patient need, grounded in scientific evidence presented by researchers, clinicians, and patient advocates. But patients need more than another moment of recognition. They need results. In 2026, the question is whether that recognition will translate into sustained action, measurable progress, and real improvements in care.